Back to discover
Drug

Etrasimod arginine

Approved · EMA

Also known as Velsipity, etrasimod (as arginine).

1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Velsipity (EMA)

Regulatory2024-02-16EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Etrasimod arginine
Aliases & brands
Velsipityetrasimod (as arginine)
RxNorm CUI
2668046
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2024-02-16
Latest approval
2024-02-16
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2024-02-16Approval
Approval: Velsipity (EMA)
Indication: Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lostShow full indication

Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.